CMN-005 by CoImmune for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

Bluebird snags more outcomes-based coverage for its $3M+ sickle cell gene therapy

A second outcomes-based agreement with an unidentified payer is now in the books for bluebird bio’s new $3.1 million sickle cell gene therapy, the company

January 5, 2024

Duchenne Muscular Dystrophy Gene Therapy

The FDA’s recent expanded approval of delandistrogene moxeparvovec (Elevidys) widened access to the gene therapy to include ambulatory and non-ambulatory Duchenne muscular dystrophy patients ages

July 2, 2024

FDA’s plan to expand device surveillance faces challenges, GAO finds

Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

August 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.